Skip to Content

InNexus Biotechnology Inc. To Host A Webcast TeleconferenceDetailing Recent News on Royalty Pharma Agreement & PreliminaryResults of DXL625 Animal Study

BRITISH COLUMBIA, Canada--(BUSINESS WIRE)--Feb 8, 2008 - InNexus Biotechnology Inc. (OTCBB: IXSBF)(TSX VENTURE: IXS), Chairman and CEO, Jeff Morhet will host awebcast teleconference on Monday, February 11, 2008 at 11:00 AM ET to discuss recent announcement with Royalty Pharma and preliminary results of an in vivo animal study exhibiting DXL625 (CD20)'s efficacy in reducing the growth rate of lymphoma cancer tumors.

Teleconference Details

InNexus will host an informative teleconference on Monday, February 11, 2008 at 11:00 AM ET to discuss its recently announced agreement with Royalty Pharma. Jeff Morhet, Chairman and CEO of InNexus, along with Wade Brooksby, Chief Financial Officer, will also discuss company focus and operations including the pre-clinical program of its lead product, DXL625 (CD20).

About InNexus

InNexus is a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXL(TM)) technology, which improves the potency of existing antibody products while opening new markets and disease applications. DXL(TM) antibodies utilize unique, novel and patented methods and technologies of InNexus.

InNexus is headquartered in British Columbia with principal management based in Scottsdale, Arizona on the campus of Mayo Clinic and has its own in-house developmental facilities. These development facilities provide validation of protein and peptide discoveries, enabling InNexus (and its strategic partners) to advance novel drug therapeutics and diagnostics. To learn more about InNexus, please visit

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this news release. This news release may contain assumptions, estimates, and other forward-looking statements that involve inherent risks and uncertainties and are subject to factors, many of which are beyond the Company's control, that may cause actual results or performance to differ materially from those currently anticipated in such statements.

Posted: February 2008